Agonistic CD40 antibodies
AssigneeMab Discovery GmbH
InventorsStephan Fischer, Karsten Beckmann
Life of this patent
Estimating the term…
Abstract
The present invention relates to humanized monoclonal antibodies or antigen-binding fragments thereof that specifically bind to human CD40 receptor and induce CD40 signaling independent of Fcγ mediated CD40 receptor crosslinking. The antibodies of the present invention bind to a CD40 epitope that overlaps with the epitope of the CD40 ligand and can activate human APCs. The present invention also provides for compositions comprising said antibodies and uses for the antibodies and compositions in the treatment of patients suffering from cancer.
Claims14
An agonistic monoclonal antibody, or an antigen-binding fragment thereof, that specifically binds to the human CD40 receptor and is capable of inducing CD40 signaling independent of Fcγ mediated CD40 receptor crosslinking:
- a) wherein the antibody comprises a VH region that is at least 85% identical to SEQ ID NO:
- 10 and comprises CDR regions CDR1H, CDR2H, and CDR3H as set forth in SEQ ID NO:
- 38, SEQ ID NO:
- 52, and SEQ ID NO:
- 66, respectively;
- and
- b) wherein the antibody comprises a VL region that is at least 85% identical to SEQ ID NO:
- 24 and comprises CDR regions CDR1L, CDR2L, and CDR3L as set forth in SEQ ID NO:
- 80, SEQ ID NO:
- 94, and SEQ ID NO:
- 108, respectively.
Dependencies are inferred from the claim text.